Search Results - "Trippoli, S."

Letter: estimating the cost‐neutral price of sofosbuvir‐based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy by Messori, A., Maratea, D., Fadda, V., Trippoli, S.

Get full text

Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants by MARATEA, D., FADDA, V., TRIPPOLI, S., MESSORI, A.

Get full text

Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference by Fadda, V., Maratea, D., Trippoli, S., Messori, A.

“…Background This study was aimed at comparing the safety of bisphosphonates in women with osteoporosis by application of equivalence testing. Methods…”
Get full text

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer : meta-analysis of randomised controlled trials by MESSORI, A, TRIPPOLI, S, VAIANI, M, GORINI, M, CORRADO, A

“…OBJECTIVES: To determine the effectiveness of ranitidine and sucralfate in the prevention of stress ulcer in critical patients and to assess if these…”
Get full text

Letter: first‐line monotherapies for chronic hepatitis B – indirect comparison between entecavir and tenofovir by Maratea, D., Fadda, V., Trippoli, S., Messori, A.

Get full text

Intramuscular IFNß-1a in multiple sclerosis: 'no proof of effectiveness' or 'proof of no effectiveness'? by Messori, A., Fadda, V., Maratea, D., Trippoli, S.

Get full text

Emerging transcatheter therapies for aortic and mitral disease by Messori, A, Trippoli, S

Get more information

Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance by Messori, A, Trippoli, S

Get more information

Letter: biological drugs for inducing remission in ulcerative colitis by Maratea, D., Fadda, V., Trippoli, S., Gatto, R., De Rosa, M., Marinai, C., Messori, A.

Get full text

Single‐drug treatments for chronic hepatitis B: summarising current information by network meta‐analysis by Messori, A., Del Santo, F., Maratea, D., Trippoli, S.

Get full text

Risk-sharing approach for managing factor VIIa reimbursement in haemophilia patients with inhibitors by MESSORI, A., TRIPPOLI, S., INNOCENTI, M., MORFINI, M.

Get full text

A Uniform Procedure for Reimbursing the Off-Label Use of Antineoplastic Drugs According to the Value-for-Money Approach by Messori, A., Fadda, V., Trippoli, S.

“…National healthcare systems as well as local institutions generally reimburse numerous off-label uses of anticancer drugs, but an explicit framework for…”
Get full text

Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia by Trippoli, S, Vaiani, M, Linari, S, Longo, G, Morfini, M, Messori, A

“…Drug Information Center, Azienda Ospedaliera Careggi, Florence, Italy. BACKGROUND AND OBJECTIVES: Although several studies have determined quality of life…”
Get full text

Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP by MESSORI, A, VAIANI, M, TRIPPOLI, S, RIGACCI, L, JERKEMAN, M, LONGO, G

“…In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in…”
Get full text

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials by Messori, A, Trippoli, S, Vaiani, M, Gorini, M, Corrado, A

“…Abstract Objectives: To determine the effectiveness of ranitidine and sucralfate in the prevention of stress ulcer in critical patients and to assess if these…”
Get full text

Dropout rates with olanzapine or risperidone: a multi-centre observational study by Pelagotti, F, Santarlasci, B, Vacca, F, Trippoli, S, Messori, A

“…In patients with schizophrenia, risperidone and olanzapine are the two most commonly used atypical anti-psychotics. A recent meta-analysis based on randomized…”
Get full text

A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma by Messori, A., Becagli, P., Trippoli, S., Tendi, E.

“…To assess the cost per life year gained of alpha interferon (IFN) as adjuvant therapy for patients with high-risk resected melanoma, we conducted a…”
Get full text

Cost-effectiveness of irinotecan in advanced colorectal cancer by Trippoli, S., Vaiani, M., Cattel, F., Messori, A.

Get full text

A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review) by Messori, A, Trippoli, S

“…The methodology of cost-effectiveness studies that use a lifetime perspective is based on the extrapolation to infinity of the survival curves. However, the…”
Get more information

Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer by MESSORI, A, BECAGLI, P, TRIPPOLI, S, TENDI, E

“…The analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with each…”
Get full text